Please login to the form below

Not currently logged in
Email:
Password:

AZ's Symbicort suffers setback

AstraZeneca has been denied approval by the FDA for the use of its asthma drug Symbicort in children aged 6-11 years old

AstraZeneca has been denied approval by the US Food and Drug Administration (FDA) for the use of its asthma drug Symbicort in children aged 6-11 years old.

The company received a Complete Response Letter (CRL) from the FDA that said the company had failed to provide adequate data to establish the appropriate doses of the individual components of Symbicort, budesonide and formoterol, and to establish how the components contribute to the complete product when used in children aged 6-11 years old. AstraZeneca will send the FDA a response to the CRL in due course.

Symbicort was approved in the US for use in children over 12 years old for long-term maintenance of asthma in July 2009. In February 2009, Symbicort was approved in the US for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema.

Current treatment with Symbicort is not affected by the CRL.

7th April 2009

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...

Infographics